SCHEMBL13711996

SCHEMBL13711996

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c(C)c1C(=O)NCC(O)COn1nnc2cccnc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 12/20 0.52
▸ PDGFRB P09619 11/20 0.52
▸ FGFR1 P11362 9/20 0.52
▸ EGFR P00533 3/20 0.52
▸ KIT P10721 3/20 0.52
▸ NEK2 P51955 3/20 0.52
▸ MELK Q14680 3/20 0.52
▸ PRKAA1 Q13131 8/20 0.51
▸ PRKAA2 P54646 7/20 0.51
▸ TLK2 Q86UE8 5/20 0.51
▸ RIOK2 Q9BVS4 3/20 0.51
▸ TLK1 Q9UKI8 3/20 0.51
▸ LRRK2 Q5S007 3/20 0.51
▸ PLK4 O00444 3/20 0.51
▸ DCLK1 O15075 3/20 0.51
▸ PDPK1 O15530 3/20 0.51
▸ DAPK3 O43293 3/20 0.51
▸ ROCK2 O75116 3/20 0.51
▸ RPS6KA5 O75582 3/20 0.51
▸ RPS6KA4 O75676 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5642503 1.00 KDR (0.52) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL5642751 0.93 PDGFRB (0.60) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL13711995 0.93 PDGFRB (0.60) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL5511277 0.89 KDR (0.49) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL13712000 0.89 KDR (0.49) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL13712821 0.86 PDGFRB (0.35) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL4488879 0.82 PDGFRB (0.36) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL4488886 0.82 PDGFRB (0.36) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL4498799 0.79 KDR (0.64) KDRPDGFRBFGFR1EGFRKIT
SCHEMBL4498793 0.79 KDR (0.64) KDRPDGFRBFGFR1EGFRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582756-B2 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors SUGEN, INC. (US) 2009-09-01 — — US disclosed
US-20080045709-A1 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS SUGEN, INC. 2008-02-21 — — US disclosed
US-7256189-B2 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors SUGEN, INC. (US) 2007-08-14 — — US disclosed
US-7256189-B2 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors SUGEN, INC. (US) 2007-08-14 — — US disclosed
US-7179910-B2 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2007-02-20 — — US disclosed
US-20070027149-A1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors SUGEN, INC. 2007-02-01 — — US disclosed
US-20070027149-A1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors SUGEN, INC. 2007-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045709-A1 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS MAP4K2, MAP4K3, CDK2 KDR 762/4885PDGFRB 687/4885FGFR1 848/4885
US-20070027149-A1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors PDPK1, MAP4K2, MAP4K3 KDR 1334/4885PDGFRB 1062/4885FGFR1 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback